JIN Rui;WANG Yu-guang;ZHANG Bing;

• 1:Beijing Shijitan Hospital
• 2:Capital Medical University
• 3:The Third Affiliated Hospital of Beijing University of Chinese Medicine
• 4:School of Materia Medica

Abstract：

Chinese patent medicine containing aconitine is the key in clinical rational drug use. These drugs contain Chuanwu,Caowu or Fuzi,and Aconitum brachypodum with functions of expelling wind-dampness or tonifying Yang,all of which shall be used by strictly following the indications and dosage. However,there are many kinds of such drugs. Not only the unfamiliar knowledge of some Chinese and Western physicians about the characteristics of them,but also the combination of multiple drugs from different clinical departments,would increase the risk of aconitine poisoning. Based on the previous research,this paper proposed three core elements " syndrome differentiation-dosage differentiation-toxicity differentiation" from the prescription review and pharmacy consulting work,and objective and standardized evaluation was used to build a risk assessment scale containing 3 categories,9 items and 36 indicators with Hulisan Jiaonang and Qufeng Zhitong Jiaonang as the example. This scale was used to evaluate the risk of a therapeutic regimen before and after the implementation. According to the verification of the existing adverse reaction cases,the risk assessment scale can be used to indicate the risk of drug treatment program and identify the risk level of drug treatment status. This paper tried to provide a methodological paradigm for scientific and objective evaluation on the safety of Chinese patent medicines,and help to identify the key links and risk prevention in the rational use by Chinese medicine physicians and pharmacists.

Key Words： Chinese patent medicine;safety evaluation;mathematical scale;aconitine;Hulisan Jiaonang;Qufeng Zhitong Jiaonang

Abstract:

Keywords:

Foundation: 国家食品药品监督管理局药品评价中心项目(2020071420118);; 北京中医药大学新奥优秀传承团队建设项目(1000062720028/001);北京中医药大学基本科研业务费项目(2015-JYB-JSMS147);; 北京中医药科技发展资金项目(QN2016-04)

Authors: JIN Rui;WANG Yu-guang;ZHANG Bing;

DOI: 10.19540/j.cnki.cjcmm.20171107.004

References：

• [1]王宇光,金锐,强思思,等.骨科中成药“辨证辨量辨毒”合理用药模式的构建与实践[J].中国中药杂志,2016,41(2):350.
• [2]温桂侠.虎力散外敷治疗Ⅱ期压疮临床疗效观察[J].山西医药杂志,2012,41(12):1341.
• [3]李淑娟,赵洁,刘爱红,等.虎力散外敷联合手臂运动防治PICC致机械性静脉炎的效果观察[J].海南医学,2015,26(5):772.
• [4]中华中医药学会.中医内科常见病诊疗指南·中医病证部分[M].北京:中国中医药出版社,2008.
• [5]章琳莉,柴璐璐.含乌头类生物碱药物的质量分析与评价[J].医学信息,2014,27(12):313.
• [6]Chan T Y.Aconite poisoning[J].Clin Toxicol,2009,47(4):279.
• [7]刘致珍.虎力散胶囊致不良反应五例报告[J].贵州医药,2006,30(7):648.
• [8]王永刚.虎力散8例不良反应和4例中毒原因浅析[J].遵义医学院学报,2010,33(5):480.
• [9]吴慧英,杜贯涛.虎力散片致乌头碱样反应1例[J].中国药师,2011(4):548.
• [10]邵佳希,黄晓英,孔飞飞.同时服用虎力散片、痹祺胶囊致不良反应1例[J].中国医药指南,2013,11(4):304.
• [11]彭绍平,朱淼,谭灵芝.虎力散胶囊治疗膝骨关节炎的有效性和安全性研究[J].心理医生,2016,22(24):99.
• [12]金锐,王宇光,薛春苗,等.中成药处方点评的标准与尺度探索(二):重复用药[J].中国医院药学杂志,2015,35(7):565.